6-K
GSK plc (GSK)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of November 2021
Commission File Number 001-15170
GlaxoSmithKline plc
(Translation of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
BLOCK LISTING SIX MONTHLY RETURN
Date: 15 November 2021
| Name of applicant: | GlaxoSmithKline plc | |||
|---|---|---|---|---|
| Name of scheme: | GlaxoSmithKline plc 2017 Deferred Annual Bonus Plan | |||
| Period of return: | From: | 1 May 2021 | To: | 31 October 2021 |
| Balance of unallotted securities under scheme(s) from previous<br>return: | 35,519 | |||
| Plus: The<br>amount by which the block scheme(s) has been increased since the<br>date of the last return (if any increase has been applied<br>for): | 230,000 | |||
| Less: Number<br>of securities issued/allotted under scheme(s) during<br>period (see LR3.5.7G): | 0 | |||
| Equals: Balance<br>under scheme(s) not yet issued/allotted at end of<br>period: | 265,519 | |||
| Name of applicant: | GlaxoSmithKline plc | |||
| --- | --- | --- | --- | --- |
| Name of scheme: | GlaxoSmithKline plc Share Save Plan 2012 | |||
| Period of return: | From: | 1 May 2021 | To: | 31 October 2021 |
| Balance of unallotted securities under scheme(s) from previous<br>return: | 382,466 | |||
| Plus: The<br>amount by which the block scheme(s) has been increased since the<br>date of the last return (if any increase has been applied<br>for): | 3,000,000 | |||
| Less: Number<br>of securities issued/allotted under scheme(s) during<br>period (see LR3.5.7G): | 313,319 | |||
| Equals: Balance<br>under scheme(s) not yet issued/allotted at end of<br>period: | 3,069,147 | |||
| Name of contact: | Victoria Whyte | |||
| --- | --- | |||
| Telephone number of contact: | 020 8047 5000 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
| GlaxoSmithKline plc | |
|---|---|
| (Registrant) | |
| Date: November<br>15, 2021 | |
| By:/s/ VICTORIA<br>WHYTE<br><br><br>-------------------------- | |
| Victoria Whyte | |
| Authorised<br>Signatory for and on | |
| behalf<br>of GlaxoSmithKline plc |